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We would like to thank Suzanne Dyer and colleagues for their comments on our Article.1 We 
would like to clarify that the Cochrane Review excluded most of the studies that were 
included in our Article in which a highly consistent pattern of AD-related biomarker changes 
(increased total-tau, phospho-tau and neurofilament light and decreased A42 concentrations 
in CSF) emerged, not only in manifest Alzheimer’s disease but also in patients with mild 
cognitive impairment. These biomarkers are backed by a solid literature regarding what types 
of pathologies they reflect;2,3 they were not derived from random screens (eg, proteomics or 
multiplex protein panels) and have been validated with both neuropathology4 and amyloid 
PET findings.5 Thus, there is, in our view, no risk that the consistent findings in the literature 
are spurious to some kind of meta-phenomenon that would be present in some patients 
seeking medical advice at memory clinics.  
However, we agree with Dyer and colleagues that in the clinical setting, the CSF biomarkers 
have to be interpreted together with data from a full medical evaluation of the patient. It is 
clear from the results of our meta-analysis that there are biomarker-negative Alzheimer’s 
disease patients and biomarker-positive patients and controls that do not have Alzheimer’s 
disease. The overlap in pathology between Alzheimer’s disease and other neurodegenerative 
disorders and the high proportion of cognitively normal elderly with Alzheimer’s disease-like 
changes (ie, plaques, tangles and neurodegeneration) preclude the CSF biomarkers from 
achieving a specificity of close to 100%. The context of the clinical biomarker use we 
advocate is identical to what is recommended in the International Working Group-2 (IWG2) 
research diagnostic criteria.6 
The performance of the CSF biomarkers in a clinical setting has been evaluated in several 
studies.7-10 At present, each laboratory has to establish their own reference limits and cut-
points, and ascertain longitudinal stability and minimise random variation in their 
measurements, which is (or should be) standard practice at this stage of clinical laboratory 
testing and results in high performance over time.11 An external global quality control 
programme to assist in this process is in place and is supported by Alzheimer’s Association.12  
Finally, what ultimately determines the true value of a diagnostic test is whether clinicians 
request it or not. CSF Alzheimer’s disease biomarkers have been used in clinical practice, and 
reimbursed by the health authorities, in several countries (eg, Sweden and Germany) for more 
than 10 years, and the demand from the clinicians for these tests is steadily increasing, despite 
that only symptomatic treatment for Alzheimer’s disease being available at present. We have 
to be prepared for the advent of disease-modifying drugs for the treatment of Alzheimer’s 
disease. We foresee a high demand from patients (and their relatives) to undergo a clinical 
evaluation to learn if their cognitive problems are due to Alzheimer’s disease pathology and, 
if so, to start treatment with disease-modifying drugs. However, since these drugs may have 
side-effects, and will most likely be expensive, it will be required by clinicians to determine 
whether Alzheimer’s disease-like phenotypes in the clinic are likely to be due to the 
pathology against which the drug candidate is directed. It is our duty as clinicians and clinical 
researchers to do everything we can to meet this need. 
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